Tumours
A neoplasm () is a type of abnormal and excessive growth, called neoplasia, of tissue. The growth of a neoplasm is uncoordinated with that of the normal surrounding tissue, and persists in growing abnormally, even if the original trigger is removed. This abnormal growth usually forms a mass, when it may be called a tumor.ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of uncertain or unknown behavior. Malignant neoplasms are also simply known as cancers and are the focus of oncology. Prior to the abnormal growth of tissue, as neoplasia, cells often …
WikipediaPublications
ENCR: European Network of Cancer Registries · 19 April 2024 English
Working groups The following recommendations were finalised in the period 2021-2023: − Urothelial tumours − Basis of Diagnosis − Incidence Date − Standard item set for cancer registries − Cancer cases in …
E-learning modules in the ENCR website (Urothelial Tumours, Sarcomas, New diagnosis and treatment, Hepatobiliary … finalised in the period 2021-2023: − Urothelial tumours − Basis of Diagnosis − Incidence Date − Standard … (CNS) tumours − Haematological Malignancies Upcoming working groups: − Multiple primary tumours registration …
ENCR: European Network of Cancer Registries · 19 April 2024 English
Corrections/modifications to the received files by the JRC and request for corrections to the registry are detailed in the 1st phase validation report. [...] ENCR Cancer Registries practices survey The …
recommendation addressing recording of multiple primary tumours was discussed. A dedicated Working Group on this … Haematological malignancies The work is ongoing. CNS tumours The work is ongoing. ENCR-IACR conference 2023: …
PAN Europe: Pesticide Action Network Europe · 9 April 2024 English
EFSA needs to improve its independence One of the crucial roles in the mission of EFSA is to be independent; its work should not be influenced by companies that have …
industry (92%)2. Such methods are used to dismiss tumours observed in animal toxicity testing of pesticides …
GlobalElectronics · 30 March 2024 English
Since its inception in 2006, the GoodElectronics Network has spearheaded efforts to push state actors and corporations in the electronics industry towards respecting workers' human rights to safe and healthy …
serious blood disorders, such as leukaemia, brain tumours, and multiple sclerosis—tragically, 76 individuals …
EU: European Union · 25 March 2024 English
Explain what Innovation Procurement is and why pull incentives complement the programme; highlight the EUs investment in a portfolio of health innovation procurement projects; demonstrate the high impact of these …
personalised diagnosis & treatment management of solid tumours and lymphomas patients. eCARE will deliver digital …
EU: European Union · 22 March 2024 English
The roadmap for ‘Medical Applications of Ionising Radiation for Better Patients’ Lives’ has been established within the Euratom Horizon 2020 EURAMED rocc-n-roll project. It takes into account the EURAMED rocc-n-roll …
including individualised doses and volumes concerning tumours and individually assessed normal tissues regarding … Combination therapies may enable the treatment of tumours that are resistant to existing therapies by attacking … are today performed to destroy these localised tumours, all under imaging control. The methods for tumour …
EU: European Union · 22 March 2024 English
The European Research Council (ERC) is the premier European funding organisation for excellent frontier research. Since its establishment in 2007, it has been a cornerstone of the EU’s research and …
label extracellular vesicles (EVs) produced by tumours, and images of these EVs (collected via multi-modal …
CADTH: Canadian Agency for Drugs and Technologies in Health · 21 March 2024 English
combination with chemotherapy for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS and who would otherwise be candidates to receive bevacizuma. [...] December …
treatment of mCRC patients with left-sided primary tumours that express wild-type RAS and who would otherwise … indicated tumour genetic biomarkers: • RAS-mutated tumours: Patients should be treated with multi-agent chemotherapy … third lines of therapy. • RAS and BRAF wild-type tumours: Patients should be treated with multi-agent chemotherapy … previous line of therapy. • BRAF V600E–mutated tumours: Patients should be treated with multi-agent chemotherapy … Additionally, patients with BRAF V600E–positive tumours should be offered encorafenib in combination with …
EU: European Union · 13 March 2024 English
The JRC manages unique nuclear infrastructures, while implementing a nuclear work programme grounded in excellent expertise and knowledge developed over the past 60 years of activities
cancer, prostate cancer, brain tumours, and neuroendocrine tumours. Several clinical institutes …
Newfoundland & Labrador Department of Health and Community Services · 12 March 2024 English
• combined use of more than one biologic DMARD will not be reimbursed) Claim notes: • Must be prescribed by a rheumatologist or internist • Approvals will be for a …
moderately differentiated pancreatic neuroendocrine tumours (pNET). 2. For the treatment of patients with unresectable … well-differentiated, non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) … previous 12 weeks • High-grade serous or endometrioid tumours classified as stage III or IV according to the … weeks • Have high-grade serous or endometrioidal tumours Renewal Criteria: • Written confirmation that the … equivalent) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) …
